After the toxic cough syrup scandal, the state FDA and CDSCO have ordered two drug manufacturing plants in MP to suspend operations, though they are not linked to cough syrup production.
Glimpse:
Two pharmaceutical units in Indore and Dewas have been ordered by Madhya Pradesh regulators to halt manufacturing operations following a risk‐based inspection. Though neither is linked to cough syrup production, the suspension underlines heightened vigilance across drug manufacturing sectors.
In a preventive action tied to the ongoing safety crisis, Madhya Pradesh’s Food and Drug Administration (FDA), jointly with the Central Drugs Standard Control Organisation (CDSCO), has ordered two drug manufacturing units in Indore and Dewas to halt production. The inspections flagged regulatory noncompliances during routine audits.
Officials clarified that neither plant was involved in making cough syrups, and no substandard products from MP are currently implicated in the toxic syrup scandal. Still, the move signals a broader enforcement posture aimed at ensuring compliance across the pharmaceutical sector. Discussions between industry bodies and regulators are underway to clarify requirements and facilitate corrective action.
“Better safe than sorry in moments like this, regulators must err on the side of caution before tragedy strikes.”
By
HB Team
